Advanced Enzyme Technologies Approves Buyback and Subsidiary Acquisition

Advanced Enzyme Technologies Ltd announced that its Board of Directors has approved the un-audited financial results for the quarter ended June 30, 2026. The board also approved a buyback of equity shares up to ₹697 million at a maximum price of ₹500 per share, representing approximately 1.24% of the paid-up capital. Additionally, the company approved the acquisition of the remaining 4.28% stake in JC Biotech Private Limited, making it a wholly-owned subsidiary, and an investment of up to ₹20 million in Advanced Nutrazyme Private Limited.